FDA’s Stephen Hahn Admits He Overstated Benefit of Convalescent Plasma on COVID-19 Patients
“The criticism is entirely justified,” he tweeted.
Pete Marovich/Getty
Food and Drug Administration Commissioner Stephen Hahn conceded Monday night that he overstated the results of using convalescent plasma on coronavirus patients. His mea culpa came after scientists publicly excoriated him for saying the treatment saved 35 out of 100 people—after he mixed up two statistical concepts: absolute risk reduction and relative risk reduction. “The criticism is entirely justified,” Hahn said on Twitter. On Sunday night, the eve of the Republican National Convention, President Trump and the FDA announced an emergency-use authorization for the plasma, which is collected from people who have recovered from COVID-19 and have antibodies. Hahn denied that politics played a role in the authorization. “We at FDA do not permit politics to enter into our scientific decisions. This happens to be a political season but FDA will remain data driven,” he tweeted.
I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma. The criticism is entirely justified. What I should have said better is that the data show a relative risk reduction not an absolute risk reduction.
— Dr. Stephen M. Hahn (@SteveFDA) August 25, 2020
See more of our coverage in your search results.
Got a tip? Send it to The Daily Beast here.
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.